Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats

Drug Metabolism and Disposition

Volumn 38, Issue 10, 2010, Pages 1779-1784

  Liu, Yi Tong ^a   Hao, Hai Ping ^a   Xie, Hong Guang ^b,c   Lai, Li ^a   Wang, Qiong ^a   Liu, Chang Xiao ^d   Wang, Guang Ji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California Washington Center   (United States)

^d TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; BERBERINE CHLORIDE; BERBERINE DERIVATIVE; BEROLINE; DEMTHYLENEBERBERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; FIRST PASS EFFECT; GASTROINTESTINAL TRACT; HYPOTHESIS; INTESTINE; INTESTINE CELL; INTESTINE PERFUSION; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SMALL INTESTINE; STOMACH;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BERBERINE; CHROMATOGRAPHY, LIQUID; ENTEROCYTES; INJECTIONS, INTRAVENOUS; INTESTINE, SMALL; LIVER; MALE; METABOLIC DETOXICATION, PHASE I; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; SUBCELLULAR FRACTIONS; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

RATTUS;

EID: 77957130129     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033936     Document Type: Article

References (23)

1. Amin AH, Subbaiah TV, and Abbasi KM (1969) Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can J Microbiol 15:1067-1076.
2. Cook TJ and Shenoy SS (2003) Intestinal permeability of chlorpyrifos using the single-pass intestinal perfusion method in the rat. Toxicology 184:125-133. (Pubitemid 36009294)
3. Cummins CL, Jacobsen W, Christians U, and Benet LZ (2004) CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther 308:143-155. (Pubitemid 38090712)
4. Hao H, Wang G, Cui N, Li J, Xie L, and Ding Z (2007) Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr Drug Metab 8:137-149. (Pubitemid 46218680)
5. Ho YT, Yang JS, Lu CC, Chiang JH, Li TC, Lin JJ, Lai KC, Liao CL, Lin JG, and Chung JG (2009) Berberine inhibits human tongue squamous carcinoma cancer tumor growth in a murine xenograft model. Phytomedicine 16:887-890.
6. Hua W, Ding L, Chen Y, Gong B, He J, and Xu G (2007) Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal 44:931-937. (Pubitemid 47095187)
7. Hwang JM, Wang CJ, Chou FP, Tseng TH, Hsieh YS, Lin WL, and Chu CY (2002) Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. Arch Toxicol 76:664-670.
8. Kim SH and Lee MG (2002) Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects. Life Sci 70:1299-1315.
9. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, et al. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10:1344-1351.
10. Kuo CL, Chi CW, and Liu TY (2004) The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203:127-137.
11. Li BX, Yang BF, Hao XM, Zhou H, and Sun MZ (2000) Study on the pharmacokinetics of berberine in single dosage and coadministration with oryzanol in rabbits and healthy volunteers. Chin Pharm J 35:33-35.
12. Liu Y, Hao H, Xie H, Lv H, Liu C, and Wang G (2009) Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. J Pharm Sci 98:4391-4401.
13. Nies AT, Herrmann E, Brom M, and Keppler D (2008) Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol 376:449-461.
14. Pan GY, Wang GJ, Liu XD, Fawcett JP, and Xie YY (2002) The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol 91:193-197.
15. Qiu F, Zhu Z, Kang N, Piao S, Qin G, and Yao X (2008) Isolation and identification of urinary metabolites of berberine in rats and humans. Drug Metab Dispos 36:2159-2165.
16. Shitara Y, Nagamatsu Y, Wada S, Sugiyama Y, and Horie T (2009) Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats. Drug Metab Dispos 37:1172-1178.
17. Tsai PL and Tsai TH (2004) Hepatobiliary excretion of berberine. Drug Metab Dispos 32:405-412.
18. van de Kerkhof EG, de Graaf IA, and Groothuis GM (2007) In vitro methods to study intestinal drug metabolism. Curr Drug Metab 8:658-675.
19. Xia CQ, Liu N, Miwa GT, and Gan LS (2007) Interactions of cyclosporin a with breast cancer resistance protein. Drug Metab Dispos 35:576-582. (Pubitemid 46513259)
20. Xie HG (2010) Personalized immunosuppressive therapy in pediatric heart transplantation: progress, pitfalls and promises. Pharmacol Ther 126:146-158.
21. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S, and Barzegar-Jalali M (2007) Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci 10:368-379. (Pubitemid 350065177)
22. Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, et al. (2010) Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59:285-292.
23. Zuo F, Nakamura N, Akao T, and Hattori M (2006) Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos 34:2064-2072.